1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Northwest Natural Holding Company issued $50 million of 5.35% senior notes due 2031 on June 4, 2026, and agreed to sell another $70 million in notes scheduled to close August 5, 2026. A separate subsidiary, NW Natural Water Company, sold $75 million of its own notes, and the holding company is not a party to or guarantor of those notes. The company says proceeds will go to general corporate purposes, including repaying existing debt.
Series E notes: $50 million at 5.35%, due June 4, 2031, issued June 4, 2026
Series F ($10 million, 5.35%, due 2031) and Series G ($60 million, 5.83%, due 2036) scheduled to close August 5, 2026
NW Natural Water Company, LLC issued $75 million of notes ($33 million due 2031 and $42 million due 2036), with no holding company guarantee
Proceeds include repayment of NW Natural Water's credit agreement debt due June 10, 2026
On June 2, 2026, TIC Solutions and its subsidiaries signed a Third Amendment to their Credit Agreement with Jefferies Finance LLC as administrative agent. The amendment lowers the interest rate on the Amendment No. 3 Term Loans by 25 basis points and raises the letter of credit sublimit to $50.0 million, with principal repayments starting September 30, 2026.
Amendment No. 3 Term Loans now bear interest at Term SOFR plus 2.50% or Base Rate plus 1.50%, at the Borrower's election
Interest rate reduced by 25.0 basis points; letter of credit sublimit increased to $50.0 million
Quarterly principal payments of 0.25% of the initial principal amount begin September 30, 2026
All other material terms of the Credit Agreement remain unchanged
Solitario's previous auditor, Assure CPA, merged into Sadler, Gibb & Associates and resigned as the company's independent registered public accounting firm. The Audit Committee approved the appointment of Sadler, Gibb as the new auditor on June 3, 2026, and the change resulted from the merger rather than a disagreement with the company.
Assure CPA, LLC merged into Sadler, Gibb & Associates under an asset purchase agreement; Solitario was notified on June 2, 2026.
The Audit Committee approved Assure's resignation and Sadler, Gibb's appointment on June 3, 2026.
Assure's audit reports for fiscal 2025 and 2024 contained no adverse opinion, disclaimer, or qualification.
The filing states there were no disagreements or reportable events with Assure during 2024, 2025, or the interim period.
Aeva Technologies priced a follow-on offering of 4,494,382 shares of common stock at $22.25 per share, with Morgan Stanley as underwriter representative. The company expects net proceeds of about $94.4 million, or about $108.7 million if the underwriters fully exercise their option, and plans to use the proceeds for general corporate purposes. Issuing new shares adds to the number of shares outstanding, which can dilute existing shareholders.
Offering of 4,494,382 shares at $22.25 per share, announced June 3, 2026
Expected net proceeds of about $94.4 million, or about $108.7 million if the 674,157-share underwriter option is fully exercised
Closing expected June 5, 2026, subject to customary closing conditions
Proceeds to be used for general corporate purposes, including AI infrastructure and Co-Packaged Optics demand
Alphabet priced underwritten offerings of Class A and Class C stock and mandatory convertible preferred depositary shares, upsized from $80 billion to a total equity raise of $84.75 billion that also includes a $40 billion at-the-market program and a $10 billion private placement to Berkshire Hathaway. The company says the proceeds fund general corporate purposes, including capital expenditures to scale AI infrastructure, and the new share issuance will dilute existing shareholders.
Class A and Class C common stock offering upsized to $18 billion from $15 billion, priced at $355.1982 and $351.8018 per share, expected to close June 4, 2026.
Depositary share offerings upsized to $16.75 billion from $15 billion, expected to close June 5, 2026; estimated net proceeds of about $16.6 billion.
Berkshire Hathaway agreed to buy $10 billion of stock in a private placement; the at-the-market program of up to $40 billion is not expected to start until the third quarter of 2026.
Alphabet expects about $30 billion of at-the-market proceeds to cover 2026 employee equity tax obligations, and 2026 capital expenditures are expected to be $180-$190 billion.
At its June 4, 2026 annual meeting, Patterson-UTI stockholders approved an amendment adding 28.9 million shares to the 2021 Long-Term Incentive Plan and elected all ten director nominees. The same day, the company completed the redemption of all approximately $482.5 million of its 3.95% Senior Notes due 2028, funded in part by a $500 million offering of 6.050% Senior Notes due 2036. The share increase expands the pool available for equity awards under the plan.
Amendment approved with 319,700,114 votes for and 7,391,767 against, plus 18,069,100 broker non-votes.
All ten director nominees elected; Julie J. Robertson had the most votes withheld, at 9,622,050.
On June 4, 2026, the company redeemed all approximately $482.5 million of its 3.95% Senior Notes due 2028 at 100% of principal, plus accrued interest.
The redemption was partly funded by $500 million of 6.050% Senior Notes due 2036, which closed May 19, 2026.
Pershing Square Inc. furnished a financial supplement for the quarter ended March 31, 2026 and the month ended April 30, 2026 as Exhibit 99.1 to a Form 8-K. For Q1 2026, fee-related earnings rose to $47.7 million from $42.4 million, while distributable earnings fell to $47.8 million from $52.3 million and the company reported a net loss attributable to PS Holdco of $147.6 million, compared with net income of $19.7 million a year earlier. The supplement also shows assets under management of $33.0 billion at April 30, 2026, up from $26.6 billion at March 31, 2026, after the combined IPO and NYSE listing closed on April 30, 2026.
Q1 2026 fee-related earnings were $47.7 million, up from $42.4 million in Q1 2025; distributable earnings were $47.8 million, down from $52.3 million.
Q1 2026 net loss attributable to PS Holdco was $147.6 million, compared with net income of $19.7 million in Q1 2025.
Total AUM for core funds and HHH rose to $33.0 billion at April 30, 2026 from $26.6 billion at March 31, 2026, including $4,879.3 million of PSUS IPO net proceeds.
The combined IPO and NYSE listing closed April 30, 2026; the company will disclose financial supplements for completed fiscal periods only going forward.
Applied Aerospace & Defense, Inc. (AADX) completed its initial public offering on June 4, 2026, selling 32,500,000 shares of common stock at $20.00 per share. The underwriters also received a 30-day option to buy up to 4,875,000 additional shares, and the company adopted new governance documents, equity plans and shareholder agreements in connection with the listing.
IPO of 32,500,000 firm shares at $20.00 per share, closed and delivered June 4, 2026
Underwriters hold a 30-day option to purchase up to 4,875,000 additional shares
Amended and restated certificate of incorporation and bylaws took effect June 2, 2026
Registration Rights Agreement and Stockholders Agreement with AA&D Holdings, LP dated June 4, 2026
Biomerica agreed on May 29, 2026 to sell 78,750 shares of Diagnosis S.A., about 6% of that Polish company, for $500,000 to buyers affiliated with CEO Zackary Irani. The buyers paid upfront in exchange for a secured 12-month note at 8% interest, pending transfer of the shares, which is expected to close within thirty days subject to Polish regulatory approvals.
Shares sold: 78,750 shares of Diagnosis S.A., about 6% of issued and outstanding shares
Purchase price: $500,000, paid by buyers in exchange for a secured promissory note
Note terms: 8% annual interest, matures 12 months from May 29, 2026, secured by a lien on the shares
Closing conditions, including Polish regulatory approvals, expected to be met within thirty days of May 29, 2026
Kevin Knight resigned as Executive Chairman and director effective June 3, 2026, and the Board appointed Lead Independent Director David Vander Ploeg as Chair. Under a retirement and consulting agreement, Knight will provide consulting services for 24 months for a fee of $20.25 million, and he forfeits all unvested equity awards. The filing says his resignation was not the result of any disagreement with the company.
Kevin Knight resigned as Executive Chairman and Board member effective June 3, 2026; the filing states no disagreement with the company on operations, policies or practices.
David Vander Ploeg, Lead Independent Director since May 2023, was appointed Chair of the Board effective upon Knight's resignation.
Knight's consulting agreement, dated June 4, 2026, provides a $20.25 million fee: $10.125 million payable June 12, 2026, and $10.125 million in monthly installments over 24 months.
Knight forfeits all unvested equity awards as of the effective date and agreed to non-solicitation, non-competition and confidentiality terms.
WesBanco's Senior Executive Vice President and Chief Risk Officer, Michael L. Perkins, will retire effective June 30, 2026, and will move to a consulting role from July 1, 2026. Under a June 3, 2026 agreement, he will be paid a monthly consulting fee of $33,334 through June 30, 2027, and his continued equity vesting depends on complying with a non-competition covenant.
Perkins retires as Chief Risk Officer effective June 30, 2026; he first informed the board on January 22, 2026.
Consulting agreement signed June 3, 2026, with services starting July 1, 2026 and running through June 30, 2027.
Monthly consulting fee of $33,334 in cash; non-compete applies during the term and for one year after.
Innospec's board increased its size from seven to eight directors and appointed Shelley Bausch as a Class II director effective July 1, 2026, with a seat on the Audit Committee. The filing describes her standard non-employee director pay, which does not involve a change in company results or outlook.
Board increased from seven to eight directors, effective June 2, 2026
Shelley Bausch appointed Class II director starting July 1, 2026, serving until the 2027 annual meeting
Bausch joins the Audit Committee as of July 1, 2026; annual cash retainer of $100,000 plus $5,000 for Audit Committee service
Expected annual equity grant value of $125,000 in February each year
Disciplined Growth Acquisition Corporation completed its initial public offering of 15,000,000 units on May 28, 2026, raising $150,000,000 in gross proceeds. On June 4, 2026, underwriters bought an additional 750,000 units under a partial exercise of the over-allotment option, adding $7,500,000, and a total of $158,287,500 from the offerings and private placements was placed in a U.S.-based trust account.
IPO of 15,000,000 units at $10.00 per unit on May 28, 2026, for gross proceeds of $150,000,000
June 4, 2026: 750,000 over-allotment units sold at $10.00 per unit, for $7,500,000 in additional gross proceeds
$158,287,500 of proceeds placed in a trust account maintained by Odyssey Transfer and Trust Company
At its June 4, 2026 annual meeting, Kaiser Aluminum stockholders re-elected three Class I directors, approved an advisory vote on executive pay, ratified Deloitte & Touche LLP as auditor for 2026, and approved an amended 2021 Equity and Incentive Compensation Plan. The amendment adds 395,000 shares for equity awards, bringing the total available under the plan to 1,183,000 shares, which sets the pool for future stock-based pay that could dilute existing holders.
Plan amendment adds 395,000 shares; total available under the Amended 2021 Plan is 1,183,000 shares
Plan approved with 94.43% of votes cast for
Say-on-pay advisory vote approved with 98.68% of votes cast for
Deloitte & Touche LLP ratified as independent auditor for 2026 with 98.20% of votes cast for
At its June 4, 2026 annual meeting, Sarepta Therapeutics stockholders approved a 2026 Equity Incentive Plan and a 2026 Employee Stock Purchase Plan, both replacing earlier plans, and re-elected five Class I directors. The approvals set the share pool for employee equity compensation, a governance matter that does not change reported financial results.
2026 Equity Incentive Plan: up to 6,286,841 shares may be issued, replacing the 2018 plan
2026 Employee Stock Purchase Plan: 1,500,000 shares available for issuance, replacing the 2013 plan
Shares entitled to vote totaled 105,571,146 as of the April 8, 2026 record date; 77.97% were present or represented
Advisory say-on-pay vote for 2025 executive pay: 45,185,398 for and 22,373,065 against
CooperCompanies reported fiscal second-quarter 2026 revenue of $1.082 billion, up 8%, and non-GAAP diluted EPS of $1.21, up 26%, while a $271.6 million net litigation charge tied to the December 2023 CooperSurgical embryo culture media recall produced a GAAP net loss of $77.9 million. The company said it has reached settlements covering over 95% of claimants and expects most payments to be made in fiscal 2026, and it updated its fiscal 2026 guidance.
Revenue of $1.082 billion, up 8% from a year earlier and up 5% organically
GAAP diluted EPS of $(0.40) versus $0.44 a year earlier; non-GAAP diluted EPS of $1.21 versus $0.96
$271.6 million net pre-tax litigation charge in SG&A: $324.1 million accrued liabilities less $52.5 million expected insurance recoveries
Fiscal 2026 guidance: total revenue of $4.285 to $4.321 billion and non-GAAP diluted EPS of $4.58 to $4.66
At its June 2, 2026 annual meeting, BioMarin stockholders elected all ten director nominees, ratified KPMG LLP as the auditor for fiscal 2026, and gave a non-binding approval to executive pay. They also approved a 7,650,000-share increase to the 2017 Equity Incentive Plan, which took effect immediately and adds shares available for equity awards.
Ten directors elected; Ian T. Clark drew the most against votes at 19,160,530.
Equity plan amendment approved with 158,561,867 for and 5,480,380 against.
Advisory say-on-pay vote approved with 142,742,800 for and 21,287,767 against.
KPMG LLP ratified for the fiscal year ending December 31, 2026, with 170,867,335 for.
On June 4, 2026, Resideo entered a second amended and restated credit agreement that provides up to approximately $2,827 million of senior secured financing, replacing its prior 2021 credit agreement. The filing says the amendment was made to facilitate the proposed spin-off of its ADI Global Distribution segment to common shareholders, and no new borrowings were made on the effective date.
Financing comprises three term loans of approximately $518 million, $590 million and $1,219 million, plus a new $500 million revolving credit facility that was undrawn at closing.
No new borrowings were made on June 4, 2026; up to $75 million of the revolver may be used for letters of credit.
Term loans mature February 12, 2028, June 14, 2031 and August 13, 2032; the revolver matures five years after the effective date.
Sachem Capital Corp. announced on June 4, 2026 that its board declared a quarterly dividend of $0.01 per common share and $0.484375 per share on its 7.75% Series A Cumulative Redeemable Preferred Stock. Both are payable on June 30, 2026 to holders of record on June 15, 2026, and the preferred payment covers the full amount accrued from March 30, 2026 through June 29, 2026.
Common stock dividend: $0.01 per share, payable June 30, 2026, to holders of record as of June 15, 2026
Preferred stock dividend: $0.484375 per share on the 7.75% Series A Cumulative Redeemable Preferred Stock, payable June 30, 2026, to holders of record as of June 15, 2026
Preferred dividend represents the full amount accrued from March 30, 2026, through and including June 29, 2026
Quanex reported results for the three months ended April 30, 2026. Net sales rose 2.2% to $462.4 million, but net income fell to $3.4 million, or $0.07 per diluted share, from $20.5 million, or $0.44, as rapid cost increases and lower volumes pressured margins. Management expects to recover some of the shortfall in the second half if volumes follow normal seasonality and inflationary pressure subsides.
Net sales were $462.4 million, up from $452.5 million, mainly from pricing, including tariff-related recoveries, and foreign exchange.
Gross margin was 25.5% versus 29.0% a year earlier; adjusted diluted EPS was $0.25 versus $0.63.
Adjusted EBITDA was $44.2 million versus $63.1 million in the prior-year quarter.
As of April 30, 2026, total debt was $715.0 million, leverage was 3.1x net debt to LTM adjusted EBITDA, and liquidity was $328.6 million.
Wealthfront reported fiscal first quarter 2027 results for the period ended April 30, 2026. Revenue rose 7% year-over-year to $90.5 million and Total Platform Assets reached a record $96.6 billion, but GAAP diluted net income fell 51% to $12.8 million, mainly due to higher stock-based compensation tied to dual-trigger stock awards recognized after the IPO.
Total revenue of $90.5 million, up 7% from $84.5 million a year earlier
GAAP diluted net income of $12.8 million, down from $25.9 million; diluted EPS of $0.07 versus $0.18
Stock-based compensation of $17.1 million versus $1.9 million a year earlier, driven by dual-trigger awards following the IPO
Adjusted EBITDA of $37.5 million, down 1%; the company repurchased over 3 million shares for over $27 million in the quarter
AN2 Therapeutics said results from a 28-day nonhuman primate study and a Phase 1 first-in-human study of its oral drug AN2-502998 for chronic Chagas disease were positive. The company plans to start a Phase 2 proof-of-concept study late this year, with the drug not yet approved and no FDA-approved Chagas treatment for adults currently available.
NHP study: 100% of treated animals achieved parasite elimination at target exposures attainable in humans, maintained through four months after treatment ended
Phase 1 study (NCT07024589) in healthy adult volunteers: generally well tolerated with no dose-limiting toxicities
Company plans to initiate a Phase 2 proof-of-concept study late this year, in collaboration with DNDi
AN2-502998 would be eligible for an FDA Tropical Disease Priority Review Voucher if approved
On June 4, 2026, Dillard's completed its merger with W.D. Company, a family holding company that held Dillard's stock for the Dillard family, with W.D. Company merging into Dillard's. The filing states there was no dilution to current shareholders, as the shares W.D. Company held were cancelled and fewer shares were issued to its former shareholders.
Dillard's issued 41,494 Class A shares and 3,985,758 Class B shares to W.D. Company shareholders, in the aggregate.
Dillard's paid $85,652.51 in cash, in the aggregate, to W.D. Company shareholders.
W.D. Company had previously held 41,496 Class A shares and 3,985,776 Class B shares of Dillard's stock.
The share issuance was made under the Section 4(a)(2) and Rule 506 of Regulation D exemptions from registration.
Zumiez reported first-quarter fiscal 2026 net sales up 4.9% to $193.3 million and an operating loss of $15.2 million, against $19.9 million a year earlier. Net loss was $13.3 million, or $0.82 per share, versus $14.3 million, or $0.79 per share, a year earlier, so the per-share loss widened even as the dollar loss narrowed. The company also gave second-quarter guidance of $210 million to $215 million in net sales and a loss of $0.08 to $0.23 per share.
Comparable sales rose 4.0% in the first quarter ended May 2, 2026; comparable sales fell 0.1% in the four weeks ended May 30, 2026.
Net loss was $13.3 million, or $0.82 per share, compared with $14.3 million, or $0.79 per share, a year earlier.
Second-quarter guidance for the three months ending August 1, 2026: net sales of $210 million to $215 million and a loss of $0.08 to $0.23 per share.
Cash and current marketable securities were $124.2 million on May 2, 2026, up from $101.0 million a year earlier; the company repurchased $6.2 million of stock in the quarter.
Samsara reported first-quarter fiscal 2027 revenue of $478.8 million, up 31% from $366.9 million a year earlier, and GAAP net income of $44.5 million, or $0.08 per share, compared with a loss of $0.04 per share a year earlier. The result includes a $30.3 million arbitration gain from its Motive matter, and the company expects revenue of $482 million to $484 million in the second quarter and $2.005 billion to $2.013 billion for fiscal 2027.
Total revenue of $478.8 million, up 31% year over year; ending ARR of $1.991 billion, up 30%.
GAAP operating income of $7.2 million, compared with a loss of $33.3 million a year earlier.
GAAP net income of $44.5 million ($0.08 per share) includes a $30.3 million arbitration award gain from the Motive matter.
Outlook: Q2 revenue of $482 million to $484 million; fiscal 2027 revenue of $2.005 billion to $2.013 billion, with GAAP profitability expected.
Interface's Compensation & Talent Development Committee approved amendments to the Executive Bonus Plan on June 2, 2026. The amended plan raises the maximum annual bonus per participant to $3.0 million and forfeits bonuses for participants terminated for cause on or before March 15 of the following year.
Maximum annual bonus per participant raised from $1.85 million to $3.0 million
Participants terminated for cause on or before March 15 of the following year forfeit bonus for that performance period
Amended plan approved June 2, 2026; full text filed as Exhibit 10.1
At its June 4, 2026 annual meeting, iHeartMedia stockholders approved a second amendment to the 2021 Long-Term Incentive Award Plan, raising the reserved Class A shares to 32,000,000 and extending grant authority through June 4, 2036. Stockholders also re-elected eight directors and approved the auditor and executive pay proposals, so the plan change may dilute existing holders to the extent new awards are granted.
Plan amendment adds 13,000,000 Class A shares, bringing the total reserved to 32,000,000; incentive stock option limit also rises by 13,000,000 shares
Plan amendment passed with 94,485,819 votes for and 4,225,053 against
Advisory say-on-pay proposal passed with 83,318,864 votes for and 15,393,581 against
Eight directors, including Robert W. Pittman and James A. Rasulo, were elected to one-year terms ending at the 2027 annual meeting
At its June 3, 2026 annual meeting, Globus Medical stockholders approved an amendment raising the shares authorized under its 2021 Equity Incentive Plan by 1,000,000, to 12,000,000 Class A shares. Stockholders also re-elected director Keith W. Pfeil and elected Robert A. Douglas to Class II terms, ratified Deloitte & Touche LLP as auditor for 2026, and approved executive compensation on an advisory basis.
Equity plan amendment: 246,228,534 for, 75,266,538 against, 79,135 abstain, 6,902,949 broker non-votes
Total shares authorized under the plan rise to 12,000,000 from 11,000,000 for incentive stock options, which are now 12,000,000
Director votes: Keith W. Pfeil 293,453,432 for and 28,120,775 withheld; Robert A. Douglas 311,683,904 for and 9,890,303 withheld
Deloitte & Touche LLP ratified for fiscal year ending December 31, 2026, with 327,965,803 for and 467,955 against
Torrid Holdings reported first quarter fiscal 2026 results for the period ended May 2, 2026, with net sales down 7.6% to $245.8 million and net income falling to $0.4 million, or $0.00 per share, from $5.9 million a year earlier. The company also issued second quarter and full year fiscal 2026 outlook, and said its quarterly net sales came in slightly above its guidance. For shareholders, the sharp drop in profit and adjusted EBITDA shows weaker earnings than the prior year, and the company's outlook points to lower second quarter sales and EBITDA than the first quarter.
Net sales fell 7.6% to $245.8 million from $266.0 million; comparable sales decreased 1.7%.
Net income was $0.4 million, or $0.00 per share, versus $5.9 million, or $0.06 per share, a year earlier.
Adjusted EBITDA was $17.6 million, or 7.2% of net sales, versus $27.1 million, or 10.2%, a year earlier.
Full year fiscal 2026 outlook: net sales of $940 million to $960 million and adjusted EBITDA of $65 million to $75 million.
Planet Labs reported fiscal first-quarter 2027 revenue of $94.2 million, up 42% year over year and described as a record, with backlog up 72% to over $906 million. The company posted a net loss of $138.9 million, compared with $12.6 million a year earlier, including a roughly $106.5 million warrant revaluation loss, and its adjusted EBITDA swung to a loss of $1.0 million from a $1.2 million profit.
Q1 revenue of $94.2 million, up 42% year over year; quarter ended April 30, 2026
Q1 net loss of $138.9 million vs. $12.6 million a year earlier, including an approximate $106.5 million warrant revaluation loss
Q2 revenue guidance of approximately $102 million to $107 million; full fiscal 2027 revenue guidance of approximately $425 million to $441 million
Cash, cash equivalents and short-term investments of $730.8 million at quarter end
Argan, Inc. reported results for the three months ended April 30, 2026, with revenue up 50.2% year over year to $291.0 million and net income of $46.1 million, or $3.24 per diluted share, versus $1.60 a year earlier. Gross margin rose to 21.0% and the company held $973.6 million in cash, cash equivalents and investments with no debt, though backlog fell to $2.8 billion from $2.9 billion.
Revenue of $291.0 million, up $97.3 million or 50.2% from $193.7 million a year earlier
Net income of $46.1 million, or $3.24 per diluted share, versus $22.6 million, or $1.60, a year earlier
Project backlog of approximately $2.8 billion at April 30, 2026, down from $2.9 billion at January 31, 2026
Quarterly cash dividend of $0.500 per share versus $0.375 a year earlier
lululemon reported first-quarter fiscal 2026 net revenue up 4% to $2.5 billion, but income from operations fell 37% to $276.9 million and diluted EPS dropped to $1.69 from $2.60. The company said headwinds led it to adjust its full-year outlook, now expecting 2026 net revenue of $11.000 billion to $11.150 billion and diluted EPS of $10.95 to $11.15.
Q1 net revenue rose 4% to $2.5 billion, but Americas net revenue fell 3%
Income from operations fell 37% to $276.9 million; gross margin decreased 410 basis points to 54.2%
Q2 2026 net revenue is expected at $2.450 billion to $2.475 billion, a decline of 3% to 2%, with diluted EPS of $1.76 to $1.81
The company repurchased 2.2 million shares for $358.3 million in the quarter and ended with $1.5 billion in cash
WD-40 Company CFO Sara Hyzer will transition from her CFO and principal accounting officer roles and is expected to become Division President, Americas once a new CFO is appointed. The company has begun an external search for a successor CFO and has not yet named one, so Hyzer remains CFO in the meantime, which leaves a leadership gap in the finance function for shareholders to watch.
Hyzer stays CFO until a successor is appointed and remains PAO until June 29, 2026
Nicholas D. Giordano, age 37, designated PAO by the board on June 1, 2026, effective June 29, 2026
Patricia Q. Olsem moves from Division President, Americas to newly created Chief Strategy and Innovation Officer role
Company will file a new 8-K once a successor CFO is named
Concrete Pumping Holdings reported second-quarter fiscal 2026 results for the quarter ended April 30, 2026, with revenue up 14% to $106.8 million and income from operations up 46% to $12.1 million. Net income attributable to common shareholders was $2.1 million, or $0.04 per diluted share, compared with a loss of $0.4 million a year earlier. The company raised its fiscal 2026 outlook for revenue, Adjusted EBITDA and free cash flow.
Revenue was $106.8 million versus $94.0 million; Adjusted EBITDA rose 17.4% to $26.4 million.
Fiscal 2026 revenue outlook is now $410.0 million to $425.0 million, up from $390.0 million to $410.0 million.
Fiscal 2026 Adjusted EBITDA outlook is now $98.0 million to $105.0 million, up from $90.0 million to $100.0 million.
Debt outstanding was $425.6 million and total available liquidity was $346.3 million, compared with $352.5 million a year earlier.
Rubrik reported results for the fiscal first quarter ended April 30, 2026, with total revenue of $387.1 million, up 39% from a year earlier, and a GAAP net loss of $41.9 million, narrower than the $102.1 million loss a year earlier. The company said it is raising all of its guided metrics for fiscal 2027, now expecting revenue of $1,638 million to $1,648 million for the full year.
Total revenue was $387.1 million, up 39% from $278.5 million; subscription ARR reached $1.57 billion, up 32%.
GAAP net loss per share was $(0.21), compared with $(0.53) a year earlier; non-GAAP diluted net income per share was $0.16.
Free cash flow was $73.6 million, compared with $33.3 million, and cash and short-term investments totaled $1.75 billion as of April 30, 2026.
Fiscal 2027 outlook: revenue of $1,638 million to $1,648 million and free cash flow of $293 million to $303 million; the filing does not state the prior ranges.
Docusign reported fiscal first-quarter 2027 results for the three months ended April 30, 2026, with revenue of $830.2 million, up 9% year over year, and GAAP diluted earnings of $0.40 per share versus $0.34 a year earlier. The company also gave guidance for the quarter ending July 31, 2026, with revenue of $865 million to $869 million, and for the fiscal year ending January 31, 2027, with revenue of $3,490 million to $3,502 million, and repurchased $317.5 million of its stock during the quarter.
Revenue was $830.2 million, up 9% year over year, including an approximately 1.6% positive impact from foreign exchange rates.
GAAP net income per diluted share was $0.40 versus $0.34; non-GAAP net income per diluted share was $1.09 versus $0.90.
Free cash flow was $289.4 million versus $227.8 million, and share repurchases were $317.5 million versus $183.4 million.
Guidance calls for fiscal 2027 revenue of $3,490 million to $3,502 million, a 9% increase, and a quarter ending July 31, 2026 revenue range of $865 million to $869 million.
Guidewire reported unaudited results for the fiscal third quarter ended April 30, 2026, with total revenue up 27% to $372.5 million and ARR up 19%. GAAP net income fell to $16.5 million from $46.0 million, which the company tied to a $20.1 million foreign currency loss, but the company raised its fiscal 2026 revenue, operating income, and operating cash flow outlook.
Total revenue was $372.5 million, up 27% from $293.5 million a year earlier; subscription and support revenue rose 35% to $244.7 million.
GAAP diluted EPS was $0.19 versus $0.54; non-GAAP diluted EPS was $0.82 versus $0.55.
Fiscal 2026 total revenue outlook is now $1,460 million to $1,470 million, and operating cash flow is expected at $365 million to $380 million.
The company repurchased 1,696,180 shares at an average price of $147.07 in the quarter, with $240.5 million left under a $500 million program.
Medpace Holdings appointed Brad W. Hansman, age 43, as Executive Vice President, Operations, effective June 1, 2026. He will perform the functions of the company's principal operating officer alongside Susan E. Burwig, the current Executive Vice President, Operations. The filing discloses a $492,250 base salary and incentive eligibility, which is a routine leadership change for shareholders.
Brad W. Hansman, age 43, appointed Executive Vice President, Operations, effective June 1, 2026
Hansman will share principal operating officer duties with Susan E. Burwig
Annual base salary of $492,250, plus eligibility for short-term incentive and long-term equity plans
ServiceTitan reported fiscal first-quarter 2027 results for the period ended April 30, 2026, with total revenue up 25% to $268.8 million and a GAAP net loss of $22.8 million, down from $46.4 million a year earlier. The company also issued fiscal second-quarter revenue guidance of $284 million to $286 million and full fiscal 2027 revenue guidance of $1.13 billion to $1.14 billion, which shareholders can compare with future results.
Total revenue was $268.8 million, up 25% from $215.7 million; gross transaction volume was $21.7 billion, up 23%.
GAAP net loss was $22.8 million, or $0.24 per share, compared with a net loss of $46.4 million, or $0.51 per share, a year earlier.
Non-GAAP income from operations was $40.8 million, a 15.2% margin, versus $16.2 million (7.5%) in the prior-year quarter.
Guidance: fiscal Q2 2027 revenue of $284 million to $286 million and full fiscal 2027 revenue of $1.13 billion to $1.14 billion; the filing does not state prior guidance.
Director Mark J. Hall notified Monster Beverage's board on June 1, 2026, that he will resign from the board effective August 1, 2026, and from his employment with subsidiary Monster Energy US LLC effective April 1, 2027. He said the decision was not the result of any disagreement with the company, its management, the board or its committees. The board will reduce its size from ten to nine directors on the same date.
Board resignation effective August 1, 2026
Employment with Monster Energy US LLC ends April 1, 2027
Board size reduced from ten to nine directors effective August 1, 2026
Filing states no disagreement with the company, management, the board or its committees
At its June 2, 2026 annual meeting, GM shareholders elected all 10 Board nominees to one-year terms and approved Amendment No. 2 to the 2020 Long-Term Incentive Plan, which adds 27 million shares and extends the plan to June 3, 2036. Shareholders rejected two shareholder proposals, including one to separate the Chair and CEO roles, and will hold advisory pay votes every year.
All 10 director nominees were elected, including Mary T. Barra, with the lowest support figure at 608,267,120 votes for (Patricia F. Russo)
The shareholder proposal to separate Chair and CEO roles failed, with 152,263,297 votes for and 531,635,494 against
The 2020 LTIP amendment passed with 488,215,468 votes for and 199,829,891 against, adding 27 million shares
Shareholders chose a one-year frequency for future advisory pay votes, with 672,645,795 votes, and the Board will follow that choice
Highwoods Properties modified its $150 million unsecured bank term loan on June 3, 2026, extending the maturity from May 2027 to June 2029. The filing also lists pricing on its $200 million term loan and $750 million revolving credit facility, and the term can be extended two more years at the company's option if no defaults have occurred.
Maturity of the $150 million unsecured term loan extended from May 2027 to June 2029
Newly extended loan priced at SOFR plus 90 basis points; $200 million term loan at SOFR plus 95 basis points; $750 million revolver at SOFR plus 85 basis points
Pricing may adjust up or down by 2.5 basis points based on greenhouse gas emission reduction sustainability goals
Amendment is Exhibit 10, the Sixth Amendment to the Sixth Amended and Restated Credit Agreement, with Bank of America, N.A. as administrative agent
At its June 3, 2026 virtual annual meeting, Ideal Power's stockholders approved an amended and restated 2013 Equity Incentive Plan, which adds 800,000 authorized shares and extends the plan's term to June 3, 2036. Stockholders also elected five directors, ratified BPM LLP as auditor for fiscal 2026, and approved the executive compensation on an advisory basis, so shareholders' votes now determine the plan's expanded share pool.
The 2013 plan's authorized shares increased by 800,000, and the plan now runs to June 3, 2036.
Stockholders holding 57.68% of outstanding shares entitled to vote were represented, which met the quorum requirement.
Proposal 4 (the equity plan) received 3,624,425 for votes and 601,975 against.
BPM LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 6,988,321 votes for.
Gencor Industries appointed Raymond Cole as interim chief financial officer on June 1, 2026, under a consulting agreement with at-will employment at $32,500 per month. Cole previously served as chief financial officer of ECD Automotive Design from May 2023 to October 2024 and most recently as a consultant there until May 2026.
Raymond Cole, age 61, appointed interim Chief Financial Officer on June 1, 2026
Compensation is $32,500 per month under a consulting agreement, employment is at-will
Prior CFO role at ECD Automotive Design from May 2023 to October 2024; no related party transactions reported
On May 28, 2026, Theon International Plc converted all 1,000 outstanding shares of Kopin's Series A Convertible Preferred Stock into common stock at a conversion price of $3.00 per share. The conversion issued 2,380,973 new common shares to Theon, and the preferred stock has been retired, so no preferred shares remain outstanding. For shareholders, this changes the company's capital structure by adding common shares and removing the preferred stock, as disclosed in this filing.
Conversion date: May 28, 2026
All 1,000 Series A Convertible Preferred shares converted at $3.00 per share
Theon received 2,380,973 shares of Kopin common stock
Series A Convertible Preferred Stock retired; none outstanding
Canterbury Park Holding Corporation filed an 8-K furnishing a presentation (Exhibit 99.1) that management will give at its 2026 Annual Meeting of Shareholders on June 4, 2026. The filing contains no financial results, and the company states the presentation is furnished rather than filed under the Exchange Act.
Annual Meeting of Shareholders scheduled for June 4, 2026
Presentation attached as Exhibit 99.1 and posted on the company's investor relations website
Filing does not report financial results; the exhibit is an image file with no text in the filing
World Acceptance said interim President and CEO Janet L. Matricciani's role ended June 3, 2026, and that the separation was not due to any disagreement with the company. Executive VP and COO J. Tobin Turner was designated principal executive officer for SEC reporting purposes, and the board is continuing its search for a permanent CEO.
Janet L. Matricciani's interim CEO role ended effective June 3, 2026; her severance is conditioned on signing a separation agreement and general release
Severance includes continued base salary of $38,461.54 every two weeks through April 12, 2027, and a lump sum equal to COBRA premiums through that date
J. Tobin Turner, 51, was designated principal executive officer effective June 3, 2026, with no change to his compensation
The board is continuing its search for a permanent successor
Jack Henry & Associates said Board Chair David Foss will retire from the board effective July 15, 2026, after notifying the board on May 29, 2026. Vice Chair and Lead Independent Director Matt Flanigan will become Board Chair upon Foss's retirement, a planned succession, and the company said Foss's departure does not reflect any disagreement with the company.
David Foss retires as Board Chair and director effective July 15, 2026; he notified the board on May 29, 2026.
Matt Flanigan, Vice Chair and Lead Independent Director, will become Board Chair upon Foss's retirement.
Flanigan joined the board in 2007, has been Lead Director since 2012, and retired in 2019 as CFO of Leggett & Platt, Inc.
Foss served as President from 2014 to 2022 and CEO from 2016 to 2024, and was named Chair in 2021.
Oceanhawk Acquisition Corp. said underwriters fully exercised their over-allotment option on May 27, 2026, buying 2,400,000 additional units at $10.00 each for $24 million, bringing total units sold to 18,400,000. A total of $184,920,000 from the IPO, the option and private placement sales was placed in a segregated trust account. The trust funds and the Rights in each unit, which convert into Class A ordinary shares upon completion of an initial business combination, are the key terms for shareholders as the company seeks a business combination.
Over-allotment option exercised in full on May 27, 2026: 2,400,000 additional units at $10.00 per unit, or $24,000,000
Total units sold after the option exercise: 18,400,000
30,000 additional private placement units sold to The Benchmark Company, LLC for approximately $300,000
$184,920,000 placed in a trust account with Odyssey Transfer & Trust Company as trustee
Caleres reported first quarter 2026 net sales of $666.6 million, up 8.5%, and GAAP earnings of $0.42 per diluted share, up from $0.21 a year earlier. The company raised the low end of its full-year 2026 adjusted EPS guidance to $1.40 to $1.65 from $1.35 to $1.65, which shareholders may view as a sign of improving earnings expectations.
Q1 net sales $666.6 million, up 8.5%; Brand Portfolio up 20.6%, while Famous Footwear fell 2.5%
Q1 GAAP EPS $0.42 and adjusted EPS $0.38, versus $0.21 and $0.22 a year earlier
Full-year 2026 adjusted EPS guidance $1.40 to $1.65, versus prior $1.35 to $1.65; GAAP EPS guidance $1.44 to $1.69
Q2 2026 GAAP EPS guidance of $0.32 to $0.38 with net sales expected to rise mid-to-high-single digits
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.